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Summary
We investigated the role of glycogen synthase kinase-
3 (GSK-3), which is inactivated by AKT, for its role in
the regulation of apoptosis. Upon IL-3 withdrawal, pro-
tein levels of MCL-1 decreased but were sustained by
pharmacological inhibition of GSK-3, which prevented
cytochrome c release and apoptosis. MCL-1 was phos-
phorylated by GSK-3 at a conserved GSK-3 phosphor-
ylation site (S159). S159 phosphorylation of MCL-1
was induced by IL-3 withdrawal or PI3K inhibition and
prevented by AKT or inhibition of GSK-3, and it led to in-
creased ubiquitinylation and degradation of MCL-1. A
phosphorylation-site mutant (MCL-1S159A), expressed
in IL-3-dependent cells, showed enhanced stability
upon IL-3 withdrawal and conferred increased protec-
tion from apoptosis compared to wild-type MCL-1.
The results demonstrate that the control of MCL-1 sta-
bility by GSK-3 is an important mechanism for the reg-
ulation of apoptosis by growth factors, PI3K, and AKT.
Introduction
In addition to induction of cell growth and proliferation,
growth factors maintain cell viability, as lack of appropri-
ate growth factor stimulation will rapidly trigger apopto-
sis. A central control point for the induction of apoptosis
is the permeabilization of the mitochondrial outer mem-
brane, leading to the release of cytochrome c and other
proteins residing in the mitochondrial intermembrane
space. Mitochondrial outer membrane permeabilization
(MOMP) is controlled by the BCL-2 family of proteins,
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17, 79104 Freiburg, Germany.with proapoptotic BAX and/or BAK required for per-
meabilization (Wei et al., 2001). This is counteracted by
antiapoptotic BCL-2 family members, mainly BCL-2,
BCL-xL, and MCL-1, which sequester BAX- or BAK-
activating BH3-only proteins BIM and BID (Cheng et al.,
2001; Kuwana et al., 2005; Letai et al., 2002). Within a
short time, MOMP is followed by apoptosome formation
and caspase activation resulting in apoptosis (Green,
2005). Growth factor receptor engagement induces acti-
vation of the PI3K/AKT pathway, which prevents the re-
lease of cytochrome c (Kennedy et al., 1999).
How AKT prevents MOMP is not fully understood. AKT
phosphorylates and inhibits the proapoptotic effects
of BAD (Datta et al., 1997; del Peso et al., 1997), Foxo1
and Foxo3a (Brunet et al., 1999; Tang et al., 1999), and hu-
man caspase 9 (Cardone et al., 1998). In addition, AKT ac-
tivates antiapoptotic effects of hexokinase (Gottlob et al.,
2001), induces expression of antiapoptotic Bcl-2-family
proteins (Song et al., 2004), and engages NF-kB to block
apoptosis (Romashkova and Makarov, 1999). It is likely
that AKT may have other antiapoptotic effects as well.
The isoforms of GSK-3, GSK-3a, and GSK-3b are inac-
tivated upon phosphorylation by AKT on serine 21 and
serine 9, respectively (Cross et al., 1995). In order to
phosphorylate its substrates, GSK-3 has a requirement
for a priming phosphorylation on the substrate four
amino-acids C-terminal of the serine/threonine to be
phosphorylated (Fiol et al., 1987). Phosphorylation by
AKT at the GSK-3 N terminus generates a ‘‘pseudosub-
strate,’’ self-inhibiting GSK-3 by occupying its active
center (Frame et al., 2001).
GSK-3 plays roles in metabolic signaling by inactivat-
ing glycogen synthase (Embi et al., 1980) and IRS-1
(Eldar-Finkelman and Krebs, 1997), and in cell cycle reg-
ulation through its targets b-catenin (Yost et al., 1996),
MYC (Sears et al., 2000), cyclin D1 (Diehl et al., 1998), cy-
clin E (Welcker et al., 2003), and BCL-3 (Viatour et al.,
2004). A potential mechanism for the regulation of apo-
ptosis by GSK-3 downstream of PI3K/AKT, however,
has not been comprehensively investigated.
A number of recent studies demonstrated the induc-
tion of the antiapoptotic BCL-2 family member MCL-1
by a number of growth factors, such as stem cell factor
and IL-5 (Huang et al., 2000), IL-6 (Jourdan et al., 2003),
VEGF (Le Gouill et al., 2004), GM-CSF, and IL-3 (Wang
et al., 1999), as well as through B cell receptor stimula-
tion (Petlickovski et al., 2005). While transcription seems
to be a regulatory component in some cases, the exact
mechanism for the maintenance of MCL-1 levels pre-
venting MOMP has been elusive. Recently, survival sig-
naling of IL-7 in immature T and B cells has been demon-
strated to depend completely on MCL-1 (Opferman et al.,
2003). However, IL-7 only transiently inducedmcl-1 tran-
scription, raising the possibility of an alternative mecha-
nism by which the steady-state levels of the short-lived
MCL-1 are maintained by growth factors. In the present
study, we addressed the maintenance of MCL-1 levels
by IL-3 and identified an apoptosis-regulating path-
way branching downstream of PI3K/AKT. We show
that GSK-3 promotes the induction of apoptosis by
Molecular Cell
750Figure 1. Inhibition of GSK-3 Prevents IL-3
Withdrawal-Induced Cytochrome c Release
and Apoptosis of FL5.12 and 32Dcl3 Cells
(A) FL5.12 cells were maintained with (+) IL-3
or were deprived of IL3 for for 2, 4, or 6 hr. IL3
was then added back in the presence (+) or
absence (2) of LY294002 (20 mM). S473 phos-
phorylation of AKT and S9 phosphorylation of
GSK-3b were assessed using the respective
phophospecific antibodies.
(B) FL5.12 and 32Dcl3 cells were cultured
without IL-3 in the presence or absence of
the GSK-3 inhibitor CHIR-611 (0.75 mM). Apo-
ptosis was determined by AnnexinV-FITC/PI
staining. The average of triplicate samples
from one experiment is shown; error bars rep-
resent the standard deviation.
(C) FL5.12 cells were cultured in the presence
of 1 mg/l, 0.2 mg/l, or 0.05 mg/l IL-3 with or with-
out CHIR-611 (0.75 mM) for 15 hr. Cells were
left untreated (nt) or apoptosis was induced
by UV radiation (200J/m2), etoposide (2 mM),
g radiation (5 Gy), or TNF (5 ng/ml) plus CHX
(10 mg/ml) and assessed by AnnexinV-FITC/
PI staining after 4 hr (TNF/CHX) or 8 hr (all
others). The average of triplicate samples
from one experiment is shown; error bars rep-
resent the standard deviation.
(D) FL5.12 cells transduced with control vec-
tor (pLXIP) or myristoylated AKT (myr-AKT)
were deprived of IL-3. CHIR-611 was added
as indicated. Apoptosis was determined after
24 hr by Annexin V/PI staining. The average
of triplicate samples from one experiment is
shown; error bars represent the standard
deviation.
(E)FL5.12 cellsexpressing cytochrome c-GFP
were maintained in the presence (+IL-3) or
absence (2IL-3) of IL-3 or deprived of IL3 in
the presence of 0.75 mM CHIR-611 (-IL-3/
CHIR-611) or the inactive control compound
CT-98085 (2IL-3/CT-98085). Assessment of
cytochrome-GFP release from mitochondria
was performed by flow cytometry according
to the CLAMI protocol at the indicated time
points (Waterhouse et al., 2001).phosphorylation of MCL-1, leading to its degradation by
the ubiquitin-proteasome pathway and facilitating cyto-
chrome c release and apoptosis.
Results
IL-3-dependent cell lines undergo apoptosis rapidly
when deprived of IL-3. To characterize the role of
GSK-3 in growth factor withdrawal-induced apoptosis,
we first investigated the phosphorylation of AKT and
GSK-3b in IL-3-dependent FL5.12 cells. GSK-3b was
completely dephosphorylated after IL-3 depletion,
which derepresses its kinase activity (Cohen and Frame,
2001). When IL-3 was readded to the FL5.12 cells, AKT
and GSK-3b were strongly phosphorylated, which was
prevented by inhibition of PI3K by LY294002 (Figure 1A).
To investigate if GSK-3 activity is required for apoptosis
induction upon IL-3 withdrawal, we employed small
molecule inhibitors of GSK-3 (CHIR-611 and CHIR-911),
which inhibit GSK-3a and GSK-3b (Ring et al., 2003;
Wagman et al., 2004). Strikingly, apoptosis in IL-3-
dependent cell lines FL5.12 and 32Dcl3 (Figure 1B) and
BA/F3 cells (data not shown) deprived of IL-3 was pre-vented when GSK-3 was inhibited by CHIR-611 (Fig-
ure 1B) and CHIR-911 (data not shown).
Withdrawal of IL-3 sensitizes IL-3-dependent cells to
proapoptotic stimuli (Collins et al., 1992). We investi-
gated the contribution of GSK-3 to sensitization to apo-
ptosis induction upon reduced growth factor conditions.
FL5.12 cells were treated with UV radiation, etoposide,
g radiation, or TNF plus cycloheximide after culturing
them for 15 hr in conventional (1 mg/l) or reduced con-
centrations (0.2 and 0.05 mg/l) of IL-3. As expected, re-
duced concentrations of IL-3 sensitized the cells to the
various proapoptotic stimuli. When cells were cultured
in the presence of the GSK-3 inhibitor CHIR-611, the
sensitizing effect of low IL-3 concentrations on apopto-
sis induction by etoposide, UV, or g radiation was abro-
gated, while apoptosis induction by TNF plus cyclohex-
imide was unaffected (Figure 1C). This suggests that
inhibition of GSK-3 is an important function of IL-3 for
the prevention of apoptosis by the mitochondrial path-
way engaged by these stressors.
To compare prevention of apoptosis by GSK-3 inhibi-
tion to the protection mediated by AKT, we introduced
myristoylated AKT into FL5.12 cells and withdrew IL-3
GSK-3 Destabilizes MCL-1
751Figure 2. GSK-3 Activity Leads to Reduction
of MCL-1 upon IL-3 Withdrawal, which Does
Not Depend on Caspase Activity
(A) FL5.12, 32Dcl3, and BA/F3 cells were
maintained in the presence (+IL3) or absence
of IL-3 (2IL-3) for 6, 8, or 10 hr in the presence
of 0.75 mM CHIR-611 (+) or an equal volume of
DMSO (2). Immunoblotting was performed
for MCL-1 and BCL-2.
(B) FL5.12 cells stably expressing BCL-xL
were maintained in the presence (+IL-3) or
absence (2IL-3) of IL-3 for 6 or 9 hr with
0.75 mM CHIR-611 (+) or DMSO (2). Immuno-
blotting was performed for MCL-1, BCL-2,
and VAV1.
(C)FL5.12cells expressing BCL-xL weremain-
tained with IL-3 in the presence of 20 mM
LY294002 (+) or DMSO (2) for 4 hr, and subcel-
lular fractionation into heavy membrane (HM)
and cytosolic (cyto) fractions was performed
as described (Kluck et al., 2000). Immunoblots
were probed for MCL-1 and BAK.for 24 hr. Inhibition of GSK-3 protected the cells from ap-
optosis to the same degree as did expression of myris-
toylated-AKT (Figure 1D).
To determine if GSK-3 inhibition prevents MOMP, we
generated FL5.12 cells stably expressing cytochrome
c-GFP, allowing us to follow the release of a cytochrome
c-GFP fusion protein upon IL-3 withdrawal (Goldstein
et al., 2005). In cells depleted of IL-3, cytochrome c-GFP
was released from mitochondria, beginning about 6 hr
after IL-3 withdrawal, as indicated by the loss of fluo-
rescence from digitonin-treated cells. Release of cyto-
chrome c from mitochondria was prevented upon inhibi-
tion of GSK-3 (Figure 1E), demonstrating a requirement
for GSK-3 to facilitate MOMP.
At an early stage in their maturation, lymphocytes de-
pend on MCL-1 for cytokine-mediated protection from
apoptosis (Opferman et al., 2003). Therefore, we sus-
pected that MCL-1 might play a role in the protection
mediated by IL-3, AKT, or inhibition of GSK-3 of these
hematopoetic precursor cell lines. We examined protein
levels of MCL-1 following IL-3 withdrawal and observed
a substantial decline of MCL-1 levels by 6–10 hr after re-
moval of IL-3 from FL5.12, 32D, and BA/F3 cells. This
correlated well with the onset of cytochrome c release
and was prevented when GSK-3 was inhibited pharma-
cologically (Figure 2A). Since MCL-1 is cleaved by cas-
pases during the execution of apoptosis (Han et al.,
2004; Herrant et al., 2004) (and data not shown), we
sought to prevent caspase activation by using FL5.12
cells stably expressing BCL-xL. Apoptosis of these cells
upon IL-3 withdrawal was inhibited (see Figure S1 in the
Supplemental Data available with this article online), as
shown previously (Rathmell et al., 2000). Nevertheless,
when IL-3 was removed from FL5.12 cells overexpress-
ing BCL-xL, MCL-1 protein levels decreased by 6–9 hr,ruling out MCL-1 degradation as a secondary conse-
quence of apoptosis. Again, when GSK-3 was inhibited,
the decrease in MCL-1 was prevented (Figure 2B). Like-
wise, inhibition of PI3K by LY294002 reduced MCL-1
levels both in the cytosol and in the heavy membrane
fraction of FL5.12 cells overexpressing BCL-xL, con-
firming that stability of MCL-1 is modulated by PI3K sig-
naling, independent of apoptosis induction (Figure 2C).
The inhibiton of PI3K by itself did not lead to a major in-
duction of apoptosis of FL5.12 cells (Figure S2A), con-
sistent with observations by others for 32D cells (von
Gise et al., 2001). Indeed, we observed that, unlike IL-3
deprivation, inhibition of PI3K did not induce the expres-
sion of Bim (Figure S2B). In contrast, the MAPK inhibitor
UO126 was effective in inducing Bim expression. Since
PI3K inhibition decreases MCL-1 levels but does not in-
duce apoptosis, this suggests that downregulation of
MCL1 is not sufficient by itself to cause apoptosis but
more likely sensitizes cells to apoptosis upon IL-3 dep-
rivation, perhaps by the action of Bim.
To investigate how MCL-1 levels are regulated by
GSK-3, we first analyzed mcl-1 gene transcription by
real-time RT-PCR. We did not find major changes of
mcl-1 mRNA dependent on IL-3 withdrawal and GSK-3
inhibition (Figure S3). Instead, we observed that MCL-1
protein half-life depended on GSK-3; inhibition of PI3K
decreased MCL-1 protein half-life, which was abrogated
by inhibition of GSK-3 (Figure 3A). Consistently, myris-
toylated AKT, expressed in FL5.12 cells, had the same
effect on MCL-1 half-life as did inhibition of GSK-3
(Figure 3B).
MCL-1 contains an evolutionarily conserved GSK-3
site (Figure 4A). Therefore, we suspected that the de-
crease of MCL-1 protein half-life is a consequence of di-
rect phosphorylation of MCL-1 by GSK-3. To address
Molecular Cell
752Figure 3. GSK-3 Modulates MCL-1 Protein
Half-Life
(A) FL5.12 cells were grown in the presence of
IL-3 and preincubated for 1 hr with 0.75 mM
CHIR-611 as indicated. LY294002 (20 mM)
was added for 1.5 hr as indicated, followed
by determination of protein half-life upon inhi-
bition of translation with CHX (200 mg/ml) for
the indicated time.
(B) FL5.12 cells or FL5.12 cells expressing
constitutively active AKT (myr-AKT) were
grown in the presence of IL-3, and 20 mM
LY294002 was added for 1.5 hr as indicated,
followed by determination of protein half-life
upon inhibition of translation with CHX.this, we tested the phosphorylation of MCL-1 by GSK-3
in vitro, using recombinant MCL-1 or a protein mutant
lacking the GSK-3 site, MCL-1S159A, where alanine was
substituted for serine 159. Phosphorylation of GSK-3
substrates has been demonstrated to require a priming
phosphorylation four amino acids downstream of the
amino acid phosphorylated by GSK-3 through a dif-
ferent, often constitutively active kinase (Cohen and
Frame, 2001). For this reason, we expressed His-tagged
MCL-1 and the S159A mutant in 293T cells to obtain
MCL-1 in its intracellular phosphorylated state and puri-
fied the protein by Ni2+ affinity. In the presence of re-
combinant GSK-3b, wild-type MCL-1 was phosphory-
lated in vitro, while the mutant was not (Figure 4B).
Importantly, other putative GSK-3 sites present in hu-
man MCL-1 (which are not evolutionary conserved,
however) were not phosphorylated by recombinant
GSK-3b in this assay, indicating the specificity of GSK-
3b for S159. To specifically assess S159 phosphoryla-
tion of MCL-1, we generated a phospho-S159-specific
antibody, with which we generated results similar to
those obtained using 32P (Figure 4B).
We then investigated MCL-1 phosphorylation in vivo
by expressing wild-type MCL-1 or MCL-1S159A in HeLa
cells. Wild-type MCL-1 was phosphorylated at S159
upon PI3K inhibition (allowing GSK-3 to be active). This
occurred only in the absence of GSK-3 inhibition and, im-
portantly, was only observed when the proteasome was
inhibited, suggesting that S159-phosphorylated MCL1 is
degraded by the proteasome (Figure 4C). To investigate
phosphorylation of MCL-1 in response to changes in
cytokine signaling, we introduced human MCL-1 and
MCL-1S159A into FL5.12 cells. IL3 withdrawal or inhibition
of PI3K led to phosphorylation of MCL-1 at serine 159,
which was prevented by GSK-3 inhibition (Figure 4D).
S159-phosphorylated MCL-1 in HeLa and FL5.12 cells
was only detected upon inhibition of the proteasome
(Figure 4C and data not shown). Likewise, degradation
of MCL-1 upon IL-3 withdrawal or inhibition of PI3K was
prevented by proteasome inhibition (Figure S4). This
suggests that a proteasomal degradation mechanism
is governed by S159 phosphorylation. To explore this
further, wild-type and mutant MCL-1 were expressed
in HeLa cells along with HA-tagged ubiquitin. Ubiquitiny-lation of wild-type-MCL-1, but not of MCL-1 S159A, was
detected upon PI3K inhibition. This was prevented when
GSK-3 was inhibited pharmacologically. S159-phos-
phorylated MCL-1 was detected as a high-molecular-
weight-migrating species, paralleling the appearance
of polyubiquitinylated MCL-1 (Figure 5A). Next, we em-
ployed RNA interference to knock down GSK-3a and
GSK-3b (Yu et al., 2003) and evaluated the effects on
phosphorylation of MCL-1. Knockdown of both GSK-
3a and, to a lesser extent, GSK-3b in NIH3T3 cells dimin-
ished the appearance of S159-phosphorylated high-
molecular-weight MCL-1 species. Phosphorylation of
S159 was abolished when myr-AKT was coexpressed
(Figure 5B, left panel). Reduction of either GSK-3 iso-
form had an effect on MCL-1 phosphorylation in re-
sponse to PI3K inhibition, while knockdown of GSK-3a
had a more pronounced effect than knockdown of
GSK-3b. However, this may have been the consequence
of a more efficient knockdown of GSK-3a than that of
GSK-3b. We suspect that net GSK-3 reduction is the
main reason for the diminished MCL-1 modification we
observed (Figure 5B, lower panel).
Next, we compared the half-life of MCL-1 and the
S159A mutant when overexpressed in HeLa cells. Upon
inhibition of PI3K, wild-type MCL-1 had a significantly
shorter half-life compared to the S159A mutant. The
difference between wild-type and mutant was com-
pletely abrogated, however, when GSK-3 was inhibited,
extending the half-life of wild-type MCL-1 to that of
MCL-1S159A (Figure 5C).
In order to investigate this in hematopoietic cells, we
expressed human MCL-1 in murine FL5.12 cells and
probed for the introduced MCL-1. Consistently, when
we analyzed the half-life of MCL-1 versus MCL-1S159A
in FL5.12 cells, we found a decrease of wild-type MCL-1
protein stability upon PI3K inhibition, which was pre-
vented by GSK-3 inhibition. Again, the stability of the
MCL-1S159A mutant did not depend on the activity of
GSK-3 (Figure 5D).
Since the phospho-S159-antibody was raised against
the human MCL-1 sequence, we employed Jurkat
cells to investigate the phosphorylation of endogenous
MCL-1. When cells were treated with PI3K inhibitor, a
high-molecular-weight species was detected with the
GSK-3 Destabilizes MCL-1
753Figure 4. Phosphorylation of MCL-1 by GSK-3
(A) Comparison of MCL-1 amino acid sequences from various species. The GSK-3 site is indicated in red.
(B) V5/His-tagged MCL1 and MCL1S159A were expressed and purified from 293T cells and incubated for 20 min in the presence of 20 mCi 32Pg-
ATP with or without recombinant GSK3b (500 U). The blot was assessed using a PhosphorImager and subsequently probed with a MCL1
phospho-S159-specific antibody.
(C) V5/His-tagged MCL1, MCL1S159A, or empty vector control was introduced into HeLa cells and incubated for 6 hr with 0.75 mM CHIR-611, 20
mM MG132, and 20 mM LY294002 as indicated. After pull-down with Ni2+ beads, phophoS159-MCL-1 was assessed with the anti-phospho-S159
antibody, and the blot was reprobed for MCL-1 (V5).
(D) V5/His-tagged MCL-1 or MCL-1S159A was expressed by retroviral transduction of FL5.12 cells. After 1 hr of preincubation with 10 mM MG-132,
cells were maintained in the presence or absence of IL-3 for 3 hr with or without 0.75 mM CHIR-611 or in the presence of IL-3 and LY294002 with or
without 0.75 mM CHIR-611 for 2 hr. After pull-down with Ni2+ beads, Western blots were probed with the anti-phospho-S159 antibody and for V5.phospho-S159-specific antibody after immunoprecipi-
tation of MCL-1, which was diminished by GSK-3 inhibi-
tion. While MCL-1 with the expected molecular weight of
about 40 kDa was immunoprecipitated, the phospho-
specific antibody did not detect any signal at this molec-
ular weight of MCL-1 (data not shown), suggesting that
endogenous phopho-MCL-1 is rapidly ubiquitinylated.
With an anti-MCL-1 antibody, we also detected high-
molecular-weight MCL-1 species upon PI3K inhibition,
confirming that these high-molecular-weight species
are MCL-1 (Figure 5E). Again, this strongly suggests
that, upon PI3K inhibition, MCL-1 is phosphorylated on
S159 and rapidly ubiquitinylated.
Our results suggested that expression of the phos-
phorylation-defective mutant of MCL-1 may mediate
increased protection from apoptosis in the presence of
suboptimal IL-3. To test this, we introduced MCL-1
and the S159A mutant into FL5.12 cells and maintainedthe cells at a low IL-3 concentration (which by itself did
not induce apoptosis) for 15 hr. When IL-3 was removed
subsequently, a marked protection of cells expressing
the MCL-1S159A mutant was observed (Figure 6A). While
both forms of MCL-1 were expressed at similar levels
in the presence of conventional amounts of IL-3 as as-
sessed by intracellular staining of MCL-1, at low IL-3
concentrations, MCL-1S159A levels were consistently
higher than those of wild-type MCL-1 (Figure 6B).
We had observed that FL5.12 cells showed markedly
increased apoptosis upon UV radiation when maintained
at a low concentration of IL-3 for 15 hr prior to irradiation
(Figure 1C). We therefore asked if IL-3 concentration in-
fluences the protection from UV-induced apoptosis
conferred by wild-type MCL-1 or MCL-1S159A. FL5.12
cells expressing either form of MCL-1 were maintained
with conventional or reduced concentrations of IL-3 for
15 hr. Upon induction of apoptosis by UV radiation,
Molecular Cell
754Figure 5. GSK-3 Regulates MCL-1 Half-Life
through S159 Phosphorylation
(A) MCL-1 but not MCL-1S159A is ubiquitiny-
lated upon PI3K inhibition, which is prevented
by inhibition of GSK-3. His-tagged MCL-1,
MCL-1S159A, or empty vector, together with
HA-tagged ubiquitin as indicated, were ex-
pressed in HeLa cells and incubated with
20 mM MG132, 20 mM LY294002, and 0.75 mM
CHIR-611 as indicated. After pull-down with
Ni2+ beads, the blot was probed with anti-HA
(upper panel), anti-phospho-S159 MCL-1
(middle panel), and anti-V5 (lower panel).
(B) NIH3T3 cells were transfected with plas-
mids encoding shRNA complementary to
Xenopus ASH (x), mouse GSK-3a (a), mouse
GSK-3b (b), or combined (ab), along with plas-
mids encoding human MCL-1 or MCL-1S159A
and myrAKT as indicated. After 72 hr,
LY294002 (20 mM) and MG132 (20 mM) were
added for 1.5 hr (upper panel). In a parallel ex-
periment, NIH3T3 cells were transfected with
plasmids encoding shRNA as indicated and
a plasmid encoding puromycin resistance.
After 12 hr, 10 mM puromycin was added to
eliminate nontransfected cells. After 72 hr,
disappearance of GSK-3 isoforms was ana-
lyzed by immunoblotting (lower panel).
(C) MCL-1 or MCL-1S159A was expressed in
HeLa cells for 18 hr, and then 0.75 mM CHIR-
611 and 20 mM LY294002 were added for
60 min, followed by addition of 500 mg/ml
CHX. Cells were harvested at the indicated
time points after CHX addition.
(D) Human MCL-1, MCL-1S159A, and empty
vector were expressed in FL5.12 cells for
18 hr, and then 0.75 mM CHIR-611 and
LY294002 were added for 1 hr as indicated.
MCL-1 half-life after addition of CHX was as-
sessed as above.
(E) Jurkat cells were preincubated with
MG132 (10 mM) for 1 hr, and then CHIR-611
(0.75 mM) and LY294002 (20 mM) were added
as indicated for 3 hr. After immunoprecipita-
tion of endogenous MCL-1, the blot was
probed as indicated.protection from apoptosis by MCL-1S159A was markedly
increased compared to the protection by wild-type
MCL-1 (Figure 6C). This effect was particularly evident
when low amounts of DNA encoding MCL-1 were intro-
duced into FL5.12 cells, as, under these conditions,
changes in protein stability were not masked by high
levels of synthesis. Also, relatively greater protection by
MCL-1S159A was observed in the presence of low IL-3.
Interestingly, MCL-1S159A conferred the same protection
in the presence of low IL-3 as did wild-type MCL-1 at
a conventional IL-3 concentration (Figure 6C). Taken
together, these experiments provide strong evidence
defining MCL-1 as a bona fide GSK-3 target according
to the criteria outlined by Cohen and Frame (2001).
The proapoptotic BH3-only protein BIM is induced
upon removal of IL-3 (Dijkers et al., 2000), stabilized in
the absence of growth factor signaling (Luciano et al.,
2003), and required for apoptosis due to growth factor
deprivation (Bouillet et al., 1999). We therefore asked if
MCL-1, ‘‘rescued’’ by GSK3 inhibition after IL-3 with-
drawal, contributes to inhibition of MOMP by binding
and sequestering BIM. As shown in Figure 6D, BIM
was induced after IL-3 withdrawal. Bim was not coim-munoprecipitated with MCL-1 from cells grown in the
presence of IL-3, and little BIM was detectable in
MCL-1 coimmunoprecipitations from cells grown with-
out IL-3, due to the low amout of MCL-1 present after
IL-3 withdrawal. However, upon IL-3 withdrawal and in
the presence of GSK3 inhibitor, abundant amounts of
BIM were associated with the rescued MCL-1, suggest-
ing that MCL-1 prevented BIM from inducing MOMP by
its sequestration (Figure 6D, right panel).
Discussion
In this study, we present an apoptosis-regulatory mech-
anism downstream of PI3K and demonstrate that inacti-
vation of GSK-3 is an important function of PI3K- and
AKT-mediated protection from apoptosis. Further, we
found that stabilization of MCL-1 is a vital consequence
of inactivation of GSK-3. Ultimately, this results in the
sequestration of BIM and prevention of the permeabili-
zation of the outer mitochondrial membrane in hemato-
poietic cells.
PI3K is involved in IL-7-mediated (Barata et al., 2004)
as well as IL-3-mediated survival (Songyang et al., 1997).
GSK-3 Destabilizes MCL-1
755Figure 6. Stable MCL-1 Provides Increased Protection from Cell Death and Increased BIM Sequestration
(A) Plasmids encoding MCL-1 and MCL-1S159A (4 mg) were introduced together with a plasmid encoding spectrin-GFP (10 mg) into FL5.12 cells.
Cells were maintained at a reduced concentration of IL-3 of (0.05 mg/l) for 15 hr and subsequently maintained at reduced (+IL-3) or without (2IL-3)
IL-3. Apoptosis of bright green fluorescent cells was determined by Annexin V-APC staining after 9 hr. The average of triplicate samples from one
experiment is shown; error bars represent the standard deviation.
(B) FL5.12 cells were transfected with 4 mg of plasmid encoding human MCL-1, MCL-1S159A, or empty vector, together with a plasmid encoding
spectrin-GFP (10 mg). Cells were then maintained for 15 hr in media containing 0.05 mg/l, 0.2 mg/l, or 1 mg/l IL-3. Levels of human MCL-1 in bright
green cells were determined by intracellular staining and flow cytometry. The average of triplicate samples from one experiment is shown; error
bars represent the standard deviation.
(C) Plasmids (1 mg, 2 mg, and 4 mg) encoding MCL-1 or MCL-1S159A were introduced together with a plasmid encoding spectrin-GFP (10 mg) into
FL5.12 cells. Cells were maintained at conventional (1 mg/l) or decreased (0.2 mg/l) concentrations of IL-3 for 15 hr and subsequently UV irradiated
(200 J/m2). Apoptosis of bright green fluorescent cells was determined by Annexin V-APC staining after 9 hr. The average of triplicate samples
from one experiment is shown; error bars represent the standard deviation.
(D) FL5.12 cells were grown in the presence (+IL3) or absence (2IL3) of IL-3 with or without CHIR-611 (0.75 mM) for 11 hr, and induction of BIM was
assessed by Western blotting (left panel). Immunoprecipitation was performed with anti-MCL-1 (MCL-1) and control antibody (CTR), and the
immunoprecipitates were probed for MCL-1 and BIM.Likewise, MCL-1 is absolutely required for IL-7-medi-
ated survival of immature T and B cells as well as hema-
topoietic stem cells (Opferman et al., 2003, 2005). Our
data suggest that these are requirements for compo-
nents of the same pathway. In addition to lymphocyteapoptosis, the mechanism observed in our system may
also explain a suggested role for GSK-3 in the pro-
grammed cell death of erythroid progenitors (Somer-
vaille et al., 2001). Thus, regulation of MCL-1 by GSK-3
is likely to be an important switch in the delicate
Molecular Cell
756life-or-death decisions made in immature hematopoietic
cells on their way to maturation.
An interesting aspect of GSK-3 is its inactivation by
phosphorylation, while most kinases are activated by
phosphorylation; GSK-3 can therefore function in a man-
ner opposite to that of most other kinases. For example,
while ERK phosphorylates and thereby destabilizes
proapoptotic BIM upon growth factor stimulation (Ley
et al., 2003; Luciano et al., 2003), GSK-3 phosphorylates
and destabilizes antiapoptotic MCL-1 when growth fac-
tor is low or withdrawn. The pharmacological inhibition
of GSK-3 with highly specific small molecules provided
us with the advantage that both GSK-3a and GSK-3b ac-
tivity was abrogated simultaneously with high specificity
(Wagman et al., 2004) and facilitated the finding that
GSK-3 has a major role in the regulation of apoptosis
by IL-3.
Our findings add to other well-established mecha-
nisms downstream of growth factor stimulation govern-
ing apoptosis: the phosphorylation of the BH3-only pro-
tein BAD, as well of the transcription factors FOXO1 and
FOXO3a, being transcriptional inducers of FasL and
BIM, mediate their retention in the cytoplasm by 14-3-3
and hence inactivation (Downward, 2004). PIM, a short-
lived kinase induced by IL-3, has been shown to protect
cells from apoptosis (Fox et al., 2003). Other reports
demonstrated a glucose-dependent AKT-mediated pro-
tection and showed that hexokinase activity confers
protection downstream of AKT (Gottlob et al., 2001).
Together, the integration of these signals governs the re-
sponse of the cell to a given growth factor environment.
While enforced high expression of BCL-xL can pro-
vide long-term protection from apoptosis, AKT does
not seem to provide as much long-term protection (Ed-
inger and Thompson, 2002; Plas et al., 2001). Likewise,
prevention from apoptosis by GSK-3 inhibition was in-
complete at later time points, even upon readdition of
CHIR-611. This may reflect the impact of AKT and inhibi-
tion of GSK-3 on turnover of MCL-1, rather than sustained
expression of this antiapoptotic BCL-2 family protein.
Our results support the idea that IL-3 signaling
through PI3K regulates MCL-1 protein stability rather
than mcl-1 mRNA transcription. Induction of mcl-1
mRNA by growth factors has been shown to be transient
upon growth factor stimulation (Opferman et al., 2003).
In our experiments, when we readded IL-3 directly after
washing the cells, only a slight mRNA induction by 1 hr
was observed, which did not explain the sustained dif-
ferences in the steady-state levels of this short-lived
protein, dependent on IL-3 withdrawal and GSK-3 activ-
ity. Also, GSK-3 inhibition did not induce MCL-1 mRNA,
while having a substantial effect on MCL-1 protein half-
life and therefore steady-state levels of the protein. In-
terestingly, when separated by SDS-PAGE, MCL-1 often
appears as a doublet, and, upon IL-3 withdrawal, the up-
per band disappears before the lower. This may indicate
that the upper band is the GSK-3 phosphorylated form.
However, since we only observe phospho-S159 MCL-1
when the proteasome is inhibited, it is more likely that
this upper band represents MCL-1 that has been phos-
phorylated at the ‘‘GSK-3 priming site’’ (T163).
The stability of MCL-1 may reflect the intensity of the
growth factor signal, as the decreased protection by
wild-type MCL-1 compared to the S159A mutant wasmore pronounced when the concentration of IL-3 was
decreased. Therefore, inhibition of GSK-3 by growth
factor signaling may constitute a gatekeeper function
by elevating steady-state levels of MCL-1. We observed
that, upon IL-3 withdrawal, the decrease of the steady-
state MCL-1 levels correlated well with the induction of
cytochrome c release (beginning after about 6 hr after
cytokine depletion in FL5.12 cells), suggesting that de-
crease of MCL-1 is a requirement for cytochrome c re-
lease, which is prevented by MCL-1 stabilization due
to GSK-3 inhibition. This is consistent with a report
that MCL-1 elimination is a prerequisite for BAX/BAK
activation following UV radiation, preceding mitochon-
drial translocation of BAX and BCL-xL (Nijhawan et al.,
2003).
The regulation of MCL-1 by GSK-3 resembles the reg-
ulation of MYC, which is a labile protein that is further
destabilized upon phosphorylation by GSK-3 (Sears
et al., 1999, 2000). In contrast, phosphorylation of MYC
at the GSK-3 priming serine resulted in increased stabil-
ity. Interestingly, MCL-1 similarly shows increased sta-
bility when phosphorylated on threonine 163, which rep-
resents the GSK-3 priming phosphorylation in this
protein (Domina et al., 2004). Thus, phosphorylation of
either MYC or MCL-1 at the GSK-3 priming site stabilizes
the protein, while phosphorylation by GSK-3 promotes
its accelerated degradation. However, as MYC and
MCL-1 are labile proteins in the absence of GSK-3-
mediated phosphorylation, additional mechanisms are
responsible for their turnover. Other modifiers of MCL-1
stability have been described: translationally controlled
tumor protein (TCTP) enhances MCL-1 stability (Liu
et al., 2005), whereas the BH3-only protein Noxa was
described to promote MCL-1 degradation (Willis et al.,
2005).
Recently, Mule/ARF-BP-1, a 482 kDa protein contain-
ing a BH3 domain, was identified as a major MCL-1 ubiq-
uitin ligase. Among the evolutionary conserved MCL-1
lysine residues, Mule was shown to primarily mediate
ubiquitinylation of lysines 136, 194, and 197 (Zhong
et al., 2005). These lysines are located close to the
GSK-3 phosphorylation site S159 in the MCL-1 PEST
and the BH3 domain of MCL-1 (aa 204–226), which
was shown to associate with the BH3 domain of Mule.
It is therefore tempting to speculate that MCL-1 ubiqui-
tinylation by Mule is enhanced by S159 phosphorylation
through GSK-3. Since the biological consequence of
Mule activity, degrading MCL-1 and p53 (Chen et al.,
2005), can be divergent, it is conceivable that sub-
strate-specific levels of regulation exist.
An apparent paradox regarding the proapoptotic role
of GSK-3 is the requirement of GSK-3b for survival.
Homozygous deletion of GSK-3b in mice resulted in em-
bryonic lethality during midgestation due to liver failure
resulting from reduced NF-kB activity, an effect that
was not rescued by the remaining GSK-3a (Hoeflich
et al., 2000). It is conceivable however, that GSK-3b
may play a dual role resulting in survival (in liver cells
through NF-kB) or death (in hematopoietic cells through
MCL-1 elimination). This is consistent with our finding
that GSK-3 inhibition did not protect against apoptosis
induced by TNF-a.
In addition to the hematopoietic system, regulation of
MCL-1 by GSK-3 might also play a role in neuronal
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757apoptosis. Overexpression of GSK-3b can induce apo-
ptosis of neuronal cells (Bijur et al., 2000; Crowder and
Freeman, 2000; Hetman et al., 2000; Pap and Cooper,
1998). While these reports did not clearly show that
GSK-3 actually takes part in apoptotic signaling itself,
they suggested that GSK-3 may have a role in apoptosis
downstream of PI3K/AKT. Likewise, GSK-3 inhibitors
have been demonstrated to inhibit apoptosis of cerebel-
lar granule neurons (Cross et al., 2001). Since expression
levels of MCL-1 were associated with neuroprotection
(Mori et al., 2004), this raises the intriguing possibility
that this PI3K/AKT/GSK-3/MCL-1 pathway is important
for the regulation of neuronal cell survival as well as
that of hematopoietic cells.
Experimental Procedures
Cell Culture
FL5.12 and FL5.12 BCL-xL (kindly provided by Jeff Rathmell, Duke
University, Durham, North Carolina), 32Dcl3 (ATCC), BA/F3 cells
(kindly provided by Abelardo Lo´pez-Rivas, Instituto de Parasitologia
y Biomedicina, Granada, Spain) were grown in RPMI with 10% FCS
supplemented with the antibiotics penicillin/streptomycin and 1 mg/l
recombinant interleukin-3 or GM-CSF (Peprotech, Rocky Hill, New
Jersey). For some experiments, cells were kept at low IL-3 concen-
trations of 0.2 mg/l or 0.05 mg/l for 15 hr prior to apoptosis induction.
To deplete cultures of IL-3 or GM-CSF, cells were washed twice in
PBS and once in RPMI and grown in RPMI with 10% FCS. FL5.12
BAF3 and 32D were cultured at less than 53 105 cells/ml. HeLa cells
were grown in DMEM with 10% FCS. LY294002, UO126, and MG132
were from Calbiochem, San Diego, California; Cycloheximide was
from Sigma, St. Louis, Missouri. UV irradiation was performed using
a Stratalinker (Stratagene, San Diego, California).
Pharmacological Inhibition of GSK3
The GSK-3 inhibitor CHIR-611 (also designated as CT98014) and
CHIR-911 (also known as CT99021), low-molecular-weight (MW
486 and 465, respectively) small molecules, are ATP competitive in-
hibitors of GSK-3b, giving an IC50 of 1 and 5 nmol/l, respectively, in
a cell-free binding assay (Wagman et al., 2004). These inhibitors are
approximately equipotent against both isoforms of GSK-3 (a/b).
GSK-3 inhibitors of this class exhibit >2500-fold selectivity versus
a panel of 16 other protein kinases, including CDC2 and ERK2, which
are the closest homologs of GSK-3. The concentration of GSK-3 in-
hibitor causing half-maximal glycogen synthase stimulation (EC50)
in CHO-IR cells was 75 nmol/l for CHIR-611 and 766 nmol/l for
CHIR-911 (Wagman et al., 2004). The inhibitors were diluted in
DMSO. In all experiments, the corresponding amount of DMSO
was present in exposed and control cells. In some experiments,
a small molecule compound, CT98085, which is structurally related
to CHIR-611 but inactive for inhibition of GSK-3, was included as an
additional control.
Apoptosis Assays
Apoptosis was determined by staining with Annexin V-FITC (Caltag,
Burlingame, California) and propidium iodide. GFP-expressing cells
were analyzed by labeling with Annexin V-APC (Caltag, Burlingame,
California).
Cytochrome c Release
Cytochrome c-GFP release from mitochondria was determined by
the cell-lysis-and-mitochondria-intact (CLAMI) assay as previously
described (Waterhouse et al., 2001). Briefly, after having transduced
cells with cytochrome c-GFP-fusion construct as described (Gold-
stein et al., 2005), the cell membrane was lysed by digitonin in CLAMI
buffer (250 mM sucrose, 80 mM KCL, 50 mg/ml digitonin) on ice for
5 min, then cells were diluted in 200 ml of CLAMI buffer and GFP con-
tent was analyzed by flow cytometry.
Constructs, Transfection, and Retroviral Infection
Human MCL-1 was amplified by PCR and cloned in pcDNA3.1 (Invi-
trogen, San Diego, California) using the following primers: MCL-1S,50-ATGTTTGGCCTCAAAAGAAACGC-30, and MCL-1AS, 50-TCTTAT
TAGATATGCCAAACCAGC-30. For experiments investigating pro-
tection by MCL-1 or MCL-1S159A, the C-terminal HIS/V5 was
removed by introducing a stop codon using the QuikChange Muta-
genesis Kit (Stratagene) according to the manufacturer, using the
following primers: STOPMCL-1 S, 50-GCATATCTAATAAGATAGGG
CAATTCTG-30, and STOPMCL-1 AS, 50-CAGAATTGCCCTATCTTA
TTAGATATGC-30. The S159A mutant was generated using the fol-
lowing primers: S159A, S 50-ACGGACGGGGCACTACCCTCGA-30,
and S159A AS, 50-TCGAGGGTAGTGCCCCGTCCGT-30. Myristoy-
lated Akt was cloned in pLXIN (BD Clontech), from which the neomy-
cin resistance encoding sequence was removed and replaced by a
puromycin resistance encoding sequence. HeLa, 293T, and NIH3T3
cells were transfected with Lipofectamine 2000 (Invitrogen) accord-
ing to the instructions of the manufacturer. FL5.12 cells were trans-
fected by electropration as described by others (Shimamura et al.,
2000). Producer cell supernatants containing retroviruses were
added to FL5.12 and 32Dcl3 cells in the presence of IL-3/GM-CSF
and 5 mg/ml polybrene, spun for 20 min at room temperature (RT),
and then cultured at 37ºC for 1 hr, followed by addition of media.
Constructs encoding shRNA against Xenopus-ASH transcription
factor (control), GSK-3a, and GSK-3b were kindly provided by David
Turner (University of Michigan, Ann Arbor, Michigan).
Western Blot
Cells were lysed in lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM
NaCl, 5 mM EDTA [pH 8]), 1% NP-40, 1 mM NaVO4, 20 mM NaPO4
[pH 7.6], 10 mM NaF, 3 mM b-glyceroylphosphate, and 5 mM so-
diumpyrophosphate (all from Sigma, St. Louis, Missouri); 100 mM
MG-132 (Calbiochem); and complete protease inhibitor cocktail
(Roche, Indianapolis, Indiana). Protein (10–30 mg) was separated by
SDS-PAGE, transferred on nitrocellulose membranes, and probed
with anti-phospho-S9GSK-3b, anti-phospho-S473AKT, anti-AKT
(Cell Signaling, Beverly, Massachusetts), anti-BIM (Sigma or Stress-
gen, Ann Arbor, Michigan) anti-GSK-3b (Upstate, Charlottesville,
Virginia), anti-BCL-2 (Santa Cruz, Santa Cruz, California), anti-
mouse MCL-1 (Rockland Immunochemicals, Gilbertsville, Pennsyl-
vania), anti-human MCL-1 (Pharmingen), anti-Actin (MP Chemicals,
Aurora, Ohio), anti-phospho-S159-MCL-1 (custom made by Zymed,
San Francisco, California), anti-V5 (Invitrogen), or anti-HA (Santa
Cruz).
Immunoprecipitation
Cells (1 3 108) are lysed as above except using 1% CHAPS as a de-
tergent. IP was performed with 1 mg of antibody for 4 hr; then 20 ml
washed protein A agarose beads were added and incubated for
30 min. Beads were washed with lysis buffer, lysis high salt
(400 mM NaCl), and lagain lysis buffer and separated by SDS-PAGE.
Intracellular Staining of MCL-1
Cells were fixed with 4% paraformaldehyde in PBS for 15 min at RT,
blocked with 1% BSA in PBS for 15 min at RT, permeabilized with
0.05% saponin 1% BSA in PBS for 30 min 4ºC, stained with mouse
anti-human MCL-1 (Pharmingen) or IgG ctrl 1:100 in PBS 0.05% sa-
ponin 1% BSA for 30 min at 4ºC, washed twice with PBS, and stained
with APC-conjugated anti-mouse (1:500) in PBS 0.05% saponin 1%
BSA for 30 min at 4ºC. After washing, cells were suspended in 200 ml
of PBS 1% BSA and analyzed by flow cytometry. For analysis, cells
expressing high levels of spectrin-GFP (cotransfected along with
human MCL-1) were gated. Cells were stained for MCL-1, and
mean fluorescence under each condition was determined by sub-
straction of the isotype control.
Affinity Pull-Down
Lysis was performed as above, and lysates were incubated with 20
ml washed Ni2+ beads for 2–3 hr and washed with lysis buffer, lysis
buffer containing high salt (500 mM NaCl), and lysis buffer containing
10 mM imidazol followed by a final lysis buffer wash. To produce
MCL-1 for in vitro phosphorylation experiments, His-tagged MCL-
1 or MCL-1S159A was transfected in 293T cells. The following day,
media was replaced with media containing 0.75 mM of CHIR-611,
and cells were harvested after 36 hr total time of expression.
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Protein-loaded beads (20%) produced as described above were put
in a kinase reaction according to the manufacturer with recombinant
GSK3 (New England Biolabs, Beverly, Massachusetts) and 20 mCi
adenosine 50-(g-32P)triphosphate (Amersham, Buckinghamshire,
United Kingdom) for 20 min, washed as above, and analyzed by
SDS-PAGE, autoradiography, and Western blot.
Real-Time RT-PCR
Relative expression of MCL-1 was determined by real-time RT-PCR
in comparison to the L32 housekeeping gene as described else-
where (Droin et al., 2003). Primer sequences were the following:
mMcl-1S, 50-GTGGAGTTCTTCCACGTACAGGA-30, and mMcl-1AS,
50-AGCAACACCCGCAAAAGC-30.
Supplemental Data
Supplemental Data include four figures and can be found with this
article online at http://www.molecule.org/cgi/content/full/21/6/749/
DC1/.
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